Acumen Q2 2024 Earnings Report
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $20.5 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $281.4 million as of June 30, 2024, which is expected to support operations into the first half of 2027. The company is actively enrolling subjects in ALTITUDE-AD, a Phase 2 study, and dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024.
Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease.
Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025.
Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027.
The company plans to host a virtual R&D Day on Oct. 2, 2024, providing a deep dive into the scientific rationale, Phase 1 clinical results and Phase 2 clinical plans for sabirnetug.